Retrospective analyses have further revealed that a higher density of tumor-infiltrating CD20+ B cells correlates with better responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced lung cancer patients harboring EGFR mutations [22]. The gene discussed is EGFR; the disease is lung cancer.